Psyence BioMed Shares Rise on Exclusive U.S. Ibogaine License Deal

Psyence Biomedical Ltd. (PBM) shares rose in pre-market trading on September 28, 2026, after the company announced an exclusive licensing agreement for ibogaine-based drug development in the United States. The deal is expected to strengthen the company's position in the emerging psychedelic medicine sector. Financial terms of the agreement were not disclosed. Ibogaine, a psychoactive substance derived from the African shrub Tabernanthe iboga, is being researched for treating addiction and other neurological conditions. Psyence BioMed focuses on natural psychedelic-based therapies. The stock's pre-market gain reflects investor interest in the company's expanded U.S. footprint. No regulatory timeline or clinical trial schedule was provided in the announcement.